CXCL8 and ovarian carcinoma: In another study, the SASP secretion of IL‐1β, IL‐8 and CXCL10 induced by cisplatin and irinotecan renders ovarian cancer responsive to programmed cell death 1 (PD‐1) treatment, triggering the activation of CD8+ T cells and enhancing dendritic cell infiltration.25